(13) Other operating income
Accounting and measurement policies
Other operating income
Other operating income comprises all income that cannot be allocated to net sales or finance income on account of its character.
Income from upfront payments, milestone payments, and royalties
Income from upfront payments, milestone payments, and royalties comprises consideration received by the Group from contract partners that are not customers. This relates in particular to collaboration and out-licensing agreements in the Healthcare business sector (see Note (7) “Collaboration and licensing agreements”).
Income from the revaluation of contingent considerations
The accounting treatment of contingent consideration agreed at the sale of a business as defined in IFRS 3 is shown in Note (36) “Other financial assets.”
Other operating income was broken down as follows:
€ million |
|
2023 |
|
2022 |
|---|---|---|---|---|
Income from the disposal of assets |
|
137 |
|
54 |
Income from the revaluation of contingent considerations |
|
71 |
|
6 |
Income from upfront payments, milestone payments and royalties |
|
53 |
|
105 |
Currency effects from operating activities |
|
37 |
|
– |
Income from fair value measurement of assets |
|
27 |
|
47 |
Income from the reversal of provisions for litigation |
|
25 |
|
24 |
Realized gains from currency translation |
|
15 |
|
71 |
Income from miscellaneous services |
|
13 |
|
7 |
Reversal of impairment losses on non-financial asset |
|
6 |
|
– |
Remaining other operating income |
|
66 |
|
132 |
Other operating income |
|
445 |
|
486 |
Income from asset disposals included income from the disposal of a non-strategic brand in the Healthcare business sector and a portfolio of licenses and patents in the Electronics business sector.
The increase in income from contingent consideration was due in particular to a revaluation following the achievement of milestones in connection with the biosimilars business that was sold to a subsidiary of Fresenius SE & Co. KGaA, Bad Homburg vor der Höhe, in 2017.
The reduction in upfront payments, milestone payments, and royalties was mainly due to the lower level of royalties for interferon beta products (Biogen Inc., United States) of € 45 million (2022: € 55 million) and the fact that no license income was recognized in the United States for the antidepressant Viibryd® (AbbVie Inc., United States) after income of € 27 million in the previous year.
For information on income from the reversal of provisions for litigation, see Note (27) “Other provisions”.